Global Shigella Diarrhoea Prophylaxis Market, By Treatment (Antibiotics, Fluid and Salt Replacement, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Shigella Diarrhoea Prophylaxis Market Analysis and Size
The global shigella diarrhoea prophylaxis market is expected to witness significant growth during the forecast period. The prevalence of Shigella varied from 4.9%-17.8% in non-diarrheal stools across sites, and the incidence of Shigella-attributable diarrhea was 31.8 cases per 100 child-years. Older age, low maternal education, unimproved sanitation, initiating complementary foods before 3 months, and malnutrition were risk factors for Shigella. The global shigella diarrhoea prophylaxis market is primarily boosted by the increasing prevalence of helminths infections, and vulnerable geriatric population.
Data Bridge Market Research analyses a growth rate in the global shigella diarrhoea prophylaxis market in the forecast period 2022-2029. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Shigella, also known as shigellosis, is an intestinal disease caused by shigella dysenteries, a bacterial genus belonging to the shigella class. The main sign and symptoms of shigella is a diarrhoea which is prolonged and bloody. Shigella diarrhea episodes are very severe and are expected to be found comparatively lesser in young children.
Shigella Diarrhoea Prophylaxis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment (Antibiotics, Fluid and Salt Replacement, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Aurobindo Pharma (India), Mylan N.V. (U.S.), Sagent Pharmaceuticals, Inc (U.S.), Lupin (India), Wockhardt (India), Hikma Pharmaceutical Plc (U.K.), Akorn Incorporated (U.S.)
|
|
Market Opportunities
|
|
Global Shigella Diarrhoea Prophylaxis Market Dynamics
Drivers
- Increasing Shigella Infetion
The rise significantly influences the global market for shigella infection therapy in shigella infection cases around the world. The market for shigella infection treatments is expected to be driven by developing nations in Asia and Africa.
- Awareness about Shigella Infection
The burden of shigella infection over the world is projected to decrease as a result of public health initiatives for safe water and good sanitation. It is predicted that a focus on raising knowledge of multidrug-resistant (MDR) shigellae and resistance to the medicines azithromycin, fluoroquinolone, and cephalosporin may accelerate the development of cutting-edge treatments for shigella infection.
Opportunities
- Advanced Clinical Research
The global market is projected to grow as a result of ongoing clinical trials and studies on the development of medications or treatments for shigella species, particularly in nations like China, Vietnam, Thailand, Bangladesh, Pakistan, Thailand, and Indonesia. Shigella flexneri, Shigella dysenteriae, and Shigella sonnei are the most prevalent shigella species in nations in Asia and Africa. This makes it possible for businesses to concentrate on and finance R&D in these nations.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to handle these patients and perform the treatments could curb the growth of the global shigella diarrhoea prophylaxis market over a forecast period.
- High Cost
The huge expenditure required for setting up the treatments surely hamper the market growth.
This global shigella diarrhoea prophylaxis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global shigella diarrhoea prophylaxis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Shigella Diarrhoea Prophylaxis Market Scope
The global shigella diarrhoea prophylaxis market is segmented on the basis of type, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Antibiotics
- Fluid and Salt Replacement
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Shigella Diarrhoea Prophylaxis Market Regional Analysis/Insights
The global shigella diarrhoea prophylaxis market is analysed and market size insights and trends are provided by type, technology and end-user as referenced above.
The major countries covered in the global shigella diarrhoea prophylaxis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America represent high market share for global shigella diarrhoea prophylaxis market due to the established regulatory framework, high demand of diseases specific treatment, presence of refined healthcare infrastructure and increased patient awareness level as well as high prevalence of shigella infectious.
Asia-Pacific dominates the market due to the number of generic manufacturers in this region and increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Shigella Diarrhoea Prophylaxis Market Share Analysis
The global shigella diarrhoea prophylaxis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global shigella diarrhoea prophylaxis market
Key players operating in the global shigella diarrhoea prophylaxis market include:
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Aurobindo Pharma (India)
- Mylan N.V. (U.S.)
- Sagent Pharmaceuticals, Inc (U.S.)
- Lupin (India)
- Wockhardt (India)
- Hikma Pharmaceutical Plc (U.K.)
- Akorn Incorporated (U.S.)
SKU-